Claims

Search Type State Status Topic Model Order Counting Over

As of snapshot 27745 under ledger-default@0.3.0.

Claim	Type	Assessment	Score	Review checks	References
In a single-center single-arm phase-2 trial of 20 patients with advanced fumarate-hydratase-deficient renal-cell carcinoma, first-line tislelizumab plus lenvatinib produced a 95% objective response rate and 100% disease-control rate, while grade 3-or-higher treatment-related adverse events occurred in 45%.	QUANTITATIVE	Supported	0.8581	1 of 4	93